ARHGEF4 and neoplasm: Univariate analysis using Cox proportional hazards regression analysis showed that the accuracy of the immunostaining scores of PODXL, BCL7B, ARHGEF4, and ITGB1 to predict prognosis was almost the same as that of UICC TNM staging and better than that of tumor size (HR: 2.89, 95% CI: 1.78–4.68 for PODXL; HR: 2.27, 95% CI: 1.37–3.74 for BCL7B; HR: 2.39, 95% CI: 1.45–3.93 for ARHGEF4; HR: 2.50, 95% CI: 1.52–4.12 for ITGB1; HR: 2.56, 95% CI: 1.09–5.98 for UICC TNM stage III-IV; and HR: 1.72, 95% CI: 0.75–3.88 for tumor size) (Table 4).